Physician profile
Heather Oconnell
NPI 1730550799
$29,760.26
in general payments reported to CMS, 2019-2025
41 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,403 · 2022: $3,367 · 2023: $2,900 · 2024: $5,570 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $7,884 · Travel and Lodging: $1,972 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,300 · Honoraria: $1,250 · Education: $34.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,549.51 |
| Consulting Fee | $7,884.06 |
| Travel and Lodging | $1,972.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,300.00 |
| Honoraria | $1,250.00 |
| Education | $34.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $12,256.06 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,752.27 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Phadia US INC. | $1,624.68 | 2021-2024 | Immunocap |
| Glaxosmithkline, LLC. | $1,364.61 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Optinose US, INC. | $1,246.77 | 2021-2025 | |
| Genzyme Corporation | $1,062.07 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $941.81 | 2021-2025 | Hyqvia, Takhzyro, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $901.14 | 2021-2025 | Dupixent |
| Blueprint Medicines Corporation | $824.90 | 2022-2025 | Ayvakit |
| Kaleo, INC. | $796.60 | 2021-2024 | Auvi-Q |
| Csl Behring | $703.16 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Incyte Corporation | $600.70 | 2021-2025 | Opzelura, Opzelura |
| Grifols USA, LLC | $576.30 | 2022-2025 | Xembify |
| Genentech USA, INC. | $485.11 | 2022-2025 | Xolair |
| Pfizer INC. | $475.08 | 2021-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $386.46 | 2022-2025 | |
| Leo Pharma INC. | $358.12 | 2022-2025 | Adbry, Anzupgo |
| Amgen INC. | $312.11 | 2022-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $288.48 | 2021-2022 | |
| Pharming Healthcare, INC. | $278.95 | 2021-2025 | Ruconest |
| Abbvie INC. | $264.40 | 2022-2024 | |
| Baxter Healthcare | $162.58 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.63 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $145.25 | 2021-2025 | Orladeyo |
| Octapharma USA, INC. | $127.47 | 2024-2025 | Octagam Immune Globulin (Human) |
| Lilly USA, LLC | $127.13 | 2025 | Ebglyss |
| Organon LLC | $89.63 | 2025 | Vtama |
| Bio Products Laboratory USA, INC. | $85.97 | 2022 | |
| Kedrion Biopharma, INC. | $61.73 | 2023-2025 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Gc Biopharma USA, INC. | $53.97 | 2025 | Alyglo |
| Ars Pharmaceuticals Operations, INC. | $35.11 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $32.97 | 2025 | Nemluvio |
| Tersera Therapeutics LLC | $31.75 | 2024 | Quzyttir |
| Paratek Pharmaceuticals, INC. | $27.39 | 2025 | Xhance |
| Dermavant Sciences, INC. | $25.14 | 2024 | Vtama |
| Aimmune Therapeutics, INC. | $19.50 | 2022 | |
| Eyevance Pharmaceuticals LLC | $19.31 | 2021 | |
| Ionis Pharmaceuticals, INC. | $18.84 | 2025 | Dawnzera |
| Hikma Pharmaceuticals USA | $17.36 | 2025 | Ryaltris |
| X4 Pharmaceuticals, INC. | $14.58 | 2025 | Xolremdi |
| Advanced Respiratory, INC | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Oconnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.